Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended June 30, 2004. The company is an Australian biotechnology entity admitted to the ASX on the basis of commitments. The report details cash flow activities and financing for the period.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Receipts from Customers | 729 | 2,463 |
| Net Operating Cash Flows | (1,185) | (5,597) |
| Net Investing Cash Flows | (43) | (43) |
| Net Financing Cash Flows | 27,134 | 31,848 |
| Net Increase in Cash | 25,906 | 26,208 |
| Cash at End of Quarter | 29,579 | 29,579 |
Operating Expenses (Current Quarter): Staff costs were $197,000; Advertising and marketing were $14,000; Research and development were $1,532,000; Other working capital was $227,000.
Financing Activities: Proceeds from share issues totaled $29,553,000 for the quarter. Capital raising costs were $2,419,000. There were no borrowings or repayments of borrowings reported.
Liquidity: Cash on hand and at bank was $8,531,000, with deposits at call of $21,048,000. No bank overdrafts were utilized.
Material Changes
The most significant change during the quarter was a substantial increase in cash reserves driven by equity financing. Cash at the end of the quarter rose from $3,740,000 in the previous quarter to $29,579,000. This increase was primarily due to $29,553,000 in proceeds from the issuance of shares, offset by operating losses of $1,185,000 and capital raising costs of $2,419,000.
Outlook, Risks, and Unusual Items
Non-Cash Transactions: During the period, shares valued at $685,000 were issued to a consultant. This transaction affected consolidated assets and liabilities but did not involve cash flows.
Related Party Transactions: Aggregate payments to directors and associates totaled $163,000 for the quarter, described as salaries, directors' fees, and consulting fees at normal commercial rates.
Financing Facilities: The filing indicates no loan facilities or credit standby arrangements were available or used during the period.
Management Commentary: The filing does not contain specific forward-looking guidance or management commentary beyond the financial data and compliance statements.
Investor Verification Checklist
- Verify the nature and terms of the share issuance that generated $29.5 million in proceeds.
- Confirm the valuation methodology for the $685,000 in shares issued to a consultant.
- Review the specific milestones or commitments associated with the "admitted on the basis of commitments" status.
- Assess the sustainability of the cash burn rate given the $1.5 million quarterly R&D spend.
- Check for any subsequent filings regarding the utilization of the $29.5 million cash balance.